Biogen Idec BIIB reported a 22% rise in its third-quarter earnings and lifted its full-year view.
Biogen Idec now expects full-year adjusted earnings of $8.65 to $8.85 per share on revenue growth of 23% to 25%. The company in July expected earnings of $8.25 to $8.50 per share on revenue growth of 22% to 23%.
Biogen Idec's quarterly profit surged to $487.6 million, or $2.05 per share, from $398.4 million, or $1.67 per share, in the year-ago period. Excluding one-time items, its earnings climbed to $2.35 from $1.91.
Its revenue rose 32% to $1.83 billion. However, analysts were expecting earnings of $2.10 per share on revenue of $1.78 billion.
Biogen Idec shares gained 2.39% to $258.29 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in